Revenue and Profit Performance - Total revenue for Q1 2023 was RMB 61.61 million, a significant increase from RMB 31.75 million in Q1 2022[11] - Revenue from medical equipment and consumables trading surged to RMB 45.01 million in Q1 2023, up from RMB 8.11 million in Q1 2022[11] - Postpartum care services revenue decreased to RMB 7.67 million in Q1 2023 from RMB 11.87 million in Q1 2022[11] - Finance leasing income dropped to RMB 8.67 million in Q1 2023 compared to RMB 11.27 million in Q1 2022[11] - Profit before income tax increased to RMB 2.44 million in Q1 2023 from RMB 2.13 million in Q1 2022[11] - Net profit attributable to owners of the company was RMB 2.08 million in Q1 2023, slightly down from RMB 2.16 million in Q1 2022[11] - Earnings per share (basic and diluted) were RMB 0.52 cents in Q1 2023, compared to RMB 0.54 cents in Q1 2022[11] - Revenue for the period includes finance leasing income, interest income on loan receivables, income from postpartum care services, and income from trading of medical equipment and consumables in the PRC[35] - Revenue from finance leasing services decreased to RMB8.67 million in Q1 2023 from RMB11.27 million in Q1 2022[50] - Revenue from maternal and child postpartum care services decreased to RMB7.67 million in Q1 2023 from RMB11.87 million in Q1 2022[50] - Revenue from trading of medical equipment and consumables increased significantly to RMB45.01 million in Q1 2023 from RMB8.11 million in Q1 2022[50] - The Group's medical equipment and consumables trading business achieved revenue of RMB45.0 million in Q1 2023[67] - Profit attributable to owners of the Company was approximately RMB2.08 million in Q1 2023, compared to RMB2.16 million in Q1 2022[69] - Revenue increased by approximately RMB 29.9 million or 94.0%, from RMB 31.8 million in the prior period to RMB 61.6 million in the current period, primarily driven by a significant increase in medical equipment and consumables trade revenue from RMB 8.1 million to RMB 45.0 million[83] - Revenue increased by approximately RMB29.9 million (94.0%) from RMB31.8 million to RMB61.6 million, driven by a significant rise in income from trading medical equipment and consumables from RMB8.1 million to RMB45.0 million[103] - Medical equipment and consumables trading business achieved revenue of RMB45.0 million, marking a breakthrough growth in the company's revenue structure[100] - Finance leasing income decreased from RMB11.8 million to RMB8.9 million, while postpartum care services income decreased from RMB11.9 million to RMB7.7 million[103] - Profit and total comprehensive income attributable to owners of the company decreased from RMB 2.2 million to RMB 2.1 million, primarily due to a decrease in revenue from finance leasing services and maternal and child postpartum care industry services, as well as an increase in finance costs[114] Costs and Expenses - Total interest expense on financial liabilities not measured at fair value through profit or loss was RMB 3,990 thousand in 2023, compared to RMB 3,186 thousand in 2022[37] - Current tax for PRC Enterprise Income Tax was RMB 234 thousand in 2023, up from RMB 213 thousand in 2022[39] - Deferred tax increased significantly to RMB 413 thousand in 2023 from RMB 24 thousand in 2022[39] - Total staff costs decreased to RMB 10,196 thousand in 2023 from RMB 11,259 thousand in 2022[44] - Cost of inventories sold surged to RMB 36,532 thousand in 2023 from RMB 6,611 thousand in 2022[44] - Research and development costs recognized as an expense increased to RMB 848 thousand in 2023 from RMB 123 thousand in 2022[44] - Short-term lease payments decreased to RMB 356 thousand in 2023 from RMB 1,411 thousand in 2022[44] - Medical equipment and consumables sold cost increased to approximately RMB 36.5 million from RMB 6.6 million in the prior period[84] - Finance costs increased from approximately RMB 3.2 million to RMB 4.0 million, primarily due to an increase in interest on bank and other borrowings from RMB 3.0 million to RMB 3.7 million[90] - Cost of sales for medical equipment and consumables business increased to approximately RMB36.5 million from RMB6.6 million in the prior period[107] - Staff costs decreased from RMB10.1 million to approximately RMB9.5 million, primarily due to a reduction in headcount[108] - Other operating expenses decreased from approximately RMB12.0 million to RMB10.4 million, mainly due to reductions in postpartum care business expenses, short-term lease payments, and depreciation of property, plant, and equipment[111] - Other operating expenses decreased from approximately RMB 12.0 million to RMB 10.4 million, mainly due to reductions in miscellaneous expenses for maternal and child postpartum care business (from RMB 3.2 million to RMB 2.1 million), short-term lease payments (from RMB 1.4 million to RMB 0.4 million), and depreciation of property, plant, and equipment (from RMB 1.9 million to RMB 1.1 million)[112] Taxation - The tax rate for most PRC subsidiaries is 25%, except for one subsidiary recognized as a high technology enterprise, which enjoys a preferential tax rate of 15%[39] - Certain PRC subsidiaries qualified as small low-profit enterprises, with taxable income not exceeding RMB 1.0 million taxed at 12.5%, and income exceeding RMB 1.0 million but not exceeding RMB 3.0 million taxed at 50% of the taxable income[90] - The Group's subsidiaries in China are subject to an enterprise income tax rate of 25%, except for one subsidiary which qualifies for a preferential rate of 15%[59] Corporate Governance and Shareholding - The company's controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company[1] - The company's issued share capital as of 31 March 2023 was HK0.1 per share[114] - Mr. Zhang Junshen and Mr. Zhang Junwei each hold 300,000,000 shares, representing a 75% stake in the company[116] - The company did not recommend the payment of an interim dividend for the period[114] - The company's capital structure has remained unchanged since its listing on the GEM of the Stock Exchange on 9 July 2018[114] - The company confirmed that all directors complied with the Code of Conduct regarding securities transactions for the three months ended 31 March 2023[135] - The Audit Committee reviewed the unaudited condensed consolidated financial statements and confirmed compliance with applicable accounting standards and GEM Listing Rules[139] - The company has not purchased, sold, or redeemed any of its listed securities during the period[131] - The company maintains high corporate governance standards, with compliance to the CG Code except for a deviation from code provision C.2.1[129] - The controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company through Hero Global and Icon Global respectively[150] - Ms. Tang Yiping, the spouse of Mr. Zhang Junshen, is deemed to be interested in all shares in which Mr. Zhang Junshen is interested[150] - As of 31 March 2023, the directors were not aware of any other person (other than the disclosed directors or chief executive) who had or was deemed to have interests or short positions in the company's shares, underlying shares, or debentures[150] - The company and its subsidiaries did not purchase, sell, or redeem any of the company's listed securities during the period and up to the date of the report[152] - The company has adopted and complied with the Corporate Governance Code (CG Code) except for a deviation from code provision C.2.1[153] - The Audit Committee consists of non-executive director Mr. Lyu Di and independent non-executive directors Mr. Chan Chi Fung Leo and Dr. Deng Bin, with Mr. Chan Chi Fung Leo serving as the chairman[162] - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the three months ended 31 March 2023 and considers them to be in compliance with applicable accounting standards, GEM Listing Rules, and other legal requirements[168] - The roles of chairman and chief executive officer are both held by Mr. Zhang Junshen, which the Board believes ensures strong and consistent leadership without impairing the balance of power and authority[171] - The Group has established an Audit Committee in compliance with the GEM Listing Rules and the CG Code, with written terms of reference[172] - The Board comprises experienced and high-caliber individuals who meet regularly to discuss operational issues[171] - The Board has full confidence in Mr. Zhang Junshen's dual role, believing it benefits the Company's business prospects[171] - The Audit Committee was established pursuant to a resolution passed by the Directors on 12 June 2018[172] Business Strategy and Outlook - The Group recorded a segmental loss in maternal and child postpartum care services due to pandemic-related restrictions[75] - The company remains optimistic about sustaining its core business despite economic uncertainties caused by Covid-19, focusing on leveraging its existing client base and exploring opportunities in the healthcare industry[102] - The healthcare industry is expected to be a new economic breakthrough with significant value-added potential post-pandemic, prompting the company to focus on medical equipment finance leasing and trading[102] - The company has strategically entered the medical equipment and consumables trading business, targeting sectors such as medical aesthetics, dental, maternal and child care, and large hospital equipment[100] Financial Position and Equity - Total equity attributable to owners of the company increased to RMB 308.94 million as of March 31, 2023, from RMB 306.86 million at the start of the year[13] - Reversal of impairment loss of approximately RMB 0.9 million was recognized, mainly due to a decrease in total trade receivables[87]
紫元元(08223) - 2023 Q1 - 季度财报